| Literature DB >> 35547201 |
Yoann Zerbib1, Nelly Guilain2, Sébastien Eymieux3,4, Rustem Uzbekov4,5, Sandrine Castelain6,7, Emmanuelle Blanchard3,4, Catherine François6,7, Denis Chatelain2, Clément Brault1, Julien Maizel1, Philippe Roingeard3,4, Michel Slama1.
Abstract
Purpose: The objective of the present study was to provide a detailed histopathological description of fatal coronavirus disease 2019 (COVID 19), and compare the lesions in Intensive Care Unit (ICU) and non-ICU patients.Entities:
Keywords: ARDS; COVID-19; ICU; SARS-CoV-2; lung pathology
Year: 2022 PMID: 35547201 PMCID: PMC9081791 DOI: 10.3389/fmed.2022.837258
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Patient characteristics, comorbidities, and outcomes.
| Variable | Value |
| Sex: male/female ratio | 14/6 |
| Age, years [median (IQR)] | 75.5 [66.8–84.3] |
| Comorbidities, | |
| Active smoking | 5 (25%) |
| Chronic obstructive pulmonary disease | 4 (20%) |
| Hypertension | 14 (70%) |
| Cardiovascular disease | 8 (40%) |
| diabetes | 8 (40%) |
| Chronic kidney disease | 7 (35%) |
| Chronic liver disease | 1 (5%) |
| Cancer | 5 |
| Body mass index (kg/m2) | 26.4 [24.5–29.4] |
| Time between disease onset and hospital admission (d) | 3 [0.75–10.25] |
| Disease duration (time between disease onset and death) (d) | 18 [10–32] |
| Specific treatments received: | |
| Lopinavir | 2 (10%) |
| Steroids | 5 (25%) |
| Hydroxychloroquine | 3 (15%) |
| Azithromycin | 9 (45%) |
| Outcomes: | |
| Length of hospital stay | 13.5 [6–24] |
| Admission to the ICU | 8 (40%) |
| Respiratory support | 8 (40%) |
Patient characteristics, symptoms, organ failure and outcomes.
| Age Years | Sex | Comorbidities | Presenting symptoms | Time between symptom onset and hospital admission | Disease duration | Kidney damage | Myocardial damage | Admission to the ICU | Post-mortem SARS-CoV-2 RNA detection (PCR) | |
| 1 | 66 | Female |
|
| 1 | 10 | No | No | No | Lung |
| 2 | 73 | Male | None | Fever, dyspnea, confusion | 24 | 36 | Yes | No | No | Unknown |
| 3 | 83 | Male |
|
| 0 | 15 | No | Yes | No | Lung |
| 4 | 93 | Male |
|
| 14 | 18 | Yes | No | No | Lung |
| 5 | 78 | Female |
|
| 11 | 25 | No | No | No | No |
| 6 | 87 | Female |
|
| 3 | 9 | No | Yes | No | No |
| 7 | 90 | Female |
|
| 3 | 9 | Yes | No | No | No |
| 8 | 62 | Male |
|
| 12 | 39 | Yes | Yes | Yes | Lung |
| 9 | 71 | Male |
|
| 3 | 8 | Yes | Yes | No | Lung |
| 10 | 59 | Male |
|
| 0 | 17 | No | No | Yes | Lung |
| 11 | 72 | Male |
|
| 1 | 2 | - | - | No | Lung |
| 12 | 67 | Male |
|
| 0 | 27 | Yes | No | Yes | Lung |
| 13 | 82 | Male |
|
| 14 | 30 | Yes | No | Yes | Lung |
| 14 | 84 | Male |
|
| 4 | 10 | Yes | Yes | Yes | Lung |
| 15 | 85 | Male |
|
| 0 | 23 | Yes | No | No | Lung, Kidney |
| 16 | 64 | Male |
|
| 10 | 52 | Yes | Yes | Yes | Lung, Heart |
| 17 | 93 | Male |
| 1 | 1 | No | No | No | No | |
| 18 | 61 | Male |
|
| 4 | 56 | Yes | Yes | Yes | Unknown |
| 19 | 80 | Female |
|
| 7 | 55 | No | No | No | Lung |
| 20 | 73 | Female |
|
| 3 | 16 | No | Yes | Yes | No |
FIGURE 1Pathology findings for the lungs in deceased patients with COVID-19. (A) Fibrinous alveolitis; hematoxylin-eosin-saffron × 100. (B) Suppurative alveolitis with alveoli full of neutrophils and fibrin; hematoxylin-eosin-saffron, × 400. (C) Collapsed alveoli with thickened fibrous septa and an inflammatory infiltrate (lymphocytes and macrophages); hematoxylin-eosin-saffron, × 100. (D) Aspiration pneumonia with a foreign body and neutrophils in the lumen of a bronchiole; hematoxylin-eosin-saffron, × 400. (E) Bronchiolitis, lymphocytic infiltrate surrounding a bronchiole; hematoxylin-eosin-saffron, × 100. (F) Microthrombi in lung capillaries; hematoxylin-eosin-saffron, × 400. (G) Pulmonary embolism with a fibrinous thrombi in the lumen of a pulmonary artery; hematoxylin-eosin-saffron, × 100. (H) Lymphocytic vasculitis, with lymphocytic infiltrate surrounding a small pulmonary vessel; hematoxylin-eosin-saffron, ×100.
FIGURE 2Ultrastructural findings in the lungs. (A,B) Viral particles harboring the typical crown of spikes projection (white arrowheads) were present in the cytosol of lytic type I pneumocytes (PN I) in patients 11 and 12. (C) In the pneumocytes from patient 12, viral particles also accumulated in large vacuoles (the white arrow; see the inset for a higher magnification image). AL, alveolar lumen; ICT, interstitial connective tissue. (D) Lung capillaries were often obstructed with red blood cells (RBCs). In patient 10, capillary endothelial cells (CECs) occasionally contained a few isolated viral particles in small vesicles (the white arrowhead in the inset).
FIGURE 3Ultrastructural findings in the kidneys. (A) In glomeruli of patient 5, large numbers of viral particles in intracellular vacuoles (white arrows; see the inset for a higher magnification image) were found in podocytes (PO). GBM, glomerular basement membrane; fp, foot process. (B) In patient 10, glomerular capillaries showed signs of blood stasis. We also noticed vacuoles filled with smooth viral particles (white arrow) in the cytoplasm of glomerular endothelial cells (GECs). (C,D) In the tubules of patient 10 and 11, proximal tubular epithelial cells (PTECs) contained an abundant network of double-membrane vesicles (DMVs; black arrowheads), a marker of SARS-CoV-2 replication. TBM, tubular basement membrane. The DMVs are easily recognizable, with an inner membrane and an outer membrane [white arrowheads in the insets in panels (C,D)].
FIGURE 4Pathology findings for other organs in deceased patients with COVID-19. (A) Ischemic cardiomyopathy, with a fibrous scar in the myocardium; hematoxylin-eosin-saffron, ×100. (B) Cardiac amyloidosis, with eosinophilic deposits of amyloidosis around the myocytes; hematoxylin-eosin-saffron, ×400. (C) A myocardial biopsy showing a mild inflammatory infiltrate around the myocytes. (D) Liver cirrhosis: extensive fibrosis surrounding micronodules composed of small hepatocytes. Numerous cholangioles and mononuclear inflammatory infiltrates in the fibrous bands; hematoxylin-eosin-saffron, ×100.
Patient characteristics as a function of ICU admission.
| Admitted to the ICU ( | Not admitted to the ICU ( | ||
| Age | 65.5 [61.8–75.3] | 81.5 [72.8–87.8] | 0.01 |
| Sex: male/female ratio | 7/1 | 7/5 | 0.32 |
| Number of comorbidities, n | 2 [1–2.25] | 3 [2–4.5] | |
| Body mass index (kg/m2) | 27.6 [25.8–29.9] | 26.4 [23.2–29.1] | 0.26 |
| Time between disease onset and hospital admission (d) | 3.5 [0.75–8.5] | 3 [1.5–10] | 0.82 |
| Disease duration (time between disease onset and death) (d) | 33 [19.5–48.8] | 16.5 [9.3–24.5] | 0.09 |
| Time between death and biopsies (h) | 20 [15–36] | 20 [15.5–33.5] | 0.89 |
| Organ dysfunction | |||
| Kidney damage | 6 (75%) | 5 (41%) | 0.19 |
| Myocardial damage | 5 (62.5%) | 3 (25%) | 0.16 |
| SARS-CoV-2 detected in the lung biopsy | 4 (57.1%) | 8 (72.7%) | 0.62 |
| Lung histopathological examination | |||
| Diffuse/focal inflammatory lesions | 5/3 | 3/8 | 0.18 |
| Acute lesions | 3 (37.5%) | 9 (82%) | 0.07 |
| Sub-acute lesions | 8 (100%) | 10 (91%) | 1 |
| Fibrinous alveolitis | 3 (37.5%) | 2 (18.2%) | 0.6 |
| Macrophagic alveolitis | 8 (100%) | 11 (100%) | 1 |
| Neutrophilic alveolitis | 0 | 7 (63.6%) | 0.01 |
| Organizing pneumonia with fibrous buds in the alveoli | 6 (75%) | 6 (54%) | 0.69 |
| Collapsed alveoli | 6 (75%) | 7 (63%) | 0.35 |
| Thrombosis | 4 (50%) | 6 (54%) | 1 |
| Dystrophic pneumocytes | 7 (87.5%) | 6 (54%) | 0.17 |
| Macrophages in the interalveolar septa | 8 (100%) | 9 (82%) | 0.48 |
| Lymphocytes in the interalveolar septa | 5 (62.5%) | 9 (82%) | 0.60 |
| Lymphocytic vasculitis | 2 (25%) | 6 (54%) | 0.35 |
Pathology findings in the lung, by disease duration (early vs. late death).
| Early death ( | Late death ( | ||
| Admission to the ICU | 3 (30%) | 5 (50%) | 0.65 |
| SARS-CoV-2 detected in the lung biopsy | 6 (60%) | 7 (70%) | 1 |
| Histopathological assessment of the lungs: | |||
| Diffuse/focal inflammatory lesions | 1/9 | 7/2 | 0.01 |
| Acute lesions | 6 (60%) | 6 (66.7%) | 1 |
| Subacute lesions | 10 (100%) | 8 (88.9%) | 0.47 |
| Fibrinous alveolitis | 2 (20%) | 3 (33.4%) | 0.63 |
| Macrophagic alveolitis | 10 (100%) | 9 (100%) | 1 |
| Neutrophilic alveolitis | 4 (40%) | 3 (33.4%) | 1 |
| Organizing pneumonia with fibrous buds in the alveoli | 5 (50%) | 7 (77.8%) | 0.35 |
| Collapsed alveoli | 7 (70%) | 6 (66.7%) | 1 |
| Dystrophic pneumocytes | 6 (60%) | 7 (77.8%) | 0.63 |
| Macrophages in interalveolar septa | 7 (70%) | 5 (55.6%) | 0.65 |
| Lymphocytes in interalveolar septa | 10 (100%) | 8 (88.9%) | 0.47 |
| Lymphocytic vasculitis | 6 (60%) | 2 (22.3%) | 0.17 |
| Thrombosis | 5 (50%) | 7 (77.8%) | 0.35 |